To read this content please select one of the options below:

Health technology assessment processes: a North-South comparison of the evaluation and recommendation of health technologies in Canada and Chile

Cristián Mansilla (McMaster Health Forum and Health Policy PhD Program, McMaster University, Hamilton, Canada) (Department of Health Research Methods Evidence and Impact, McMaster University, Hamilton, Canada)
Lucy Kuhn-Barrientos (Ministry of Health, Government of Chile, Santiago, Chile)
Natalia Celedón (Ministry of Health, Government of Chile, Santiago, Chile)
Rafael de Feria (Centre for Health Economics Research and Evaluation, University of Technology Sydney, Sydney, Australia)
Julia Abelson (Department of Health Research Methods Evidence and Impact, McMaster University, Hamilton, Canada)

International Journal of Health Governance

ISSN: 2059-4631

Article publication date: 26 April 2022

Issue publication date: 12 August 2022

118

Abstract

Purpose

Health systems are progressively stressed by health spending, which is partially explained by the increase in the cost of health technologies. Countries have defined processes to prioritize interventions to be covered. This study aims to compare for the first time health technology assessment (HTA) processes in Canada and Chile, to explain the factors driving these decisions.

Design/methodology/approach

This is a health policy analysis comparing HTA processes in Canada and Chile. An analysis of publicly available documents in Canada (for CADTH) and Chile (for the Ministry of Health (MoH)) was carried out. A recognized political science framework (the 3-I framework) was used to explain the similarities and differences in both countries. The comparison of processes was disaggregated into eligibility and evaluation processes.

Findings

CADTH has different programmes for different types of drugs (with two separate expert committees), whereas the MoH has a unified process. Although CADTH’s recommendations have a federal scope, the final coverage is a provincial decision. In Chile, the recommendation has a national scope. In both cases, past recommendations influence the scope of the evaluation. Pharmaceutical companies and patient associations are important interest groups in both countries. Whereas manufacturers and tumour groups are able to submit applications to CADTH, the Chilean MoH prioritizes applications submitted by patient associations.

Originality/value

Institutions, interests and ideas play important roles in driving HTA decisions in Canada and Chile, which is demonstrated in this novel analysis. This paper provides a unique comparison to highly relevant policy processes in HTA, which is often a research area dominated by effectiveness and cost-effectiveness studies.

Keywords

Acknowledgements

The authors here acknowledge the invaluable contributions of Zahra Akbar, Michelle Mujoomdar and Deirdre DeJean for giving important clarifications on CADTH processes. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflict of Interest statement: Mr. Mansilla and Mr. De Feria report that they are former employees of the Chilean Ministry of Health and worked there for four and three years respectively before their current affiliations.

Citation

Mansilla, C., Kuhn-Barrientos, L., Celedón, N., de Feria, R. and Abelson, J. (2022), "Health technology assessment processes: a North-South comparison of the evaluation and recommendation of health technologies in Canada and Chile", International Journal of Health Governance, Vol. 27 No. 3, pp. 312-328. https://doi.org/10.1108/IJHG-10-2021-0108

Publisher

:

Emerald Publishing Limited

Copyright © 2022, Emerald Publishing Limited

Related articles